BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 30980847)

  • 1. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
    Cheung AC; Lammers WJ; Murillo Perez CF; van Buuren HR; Gulamhusein A; Trivedi PJ; Lazaridis KN; Ponsioen CY; Floreani A; Hirschfield GM; Corpechot C; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Nevens F; Thorburn D; Mason AL; Carbone M; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lindor KD; Lleo A; Poupon R; Janssen HLA; Hansen BE;
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2076-2084.e2. PubMed ID: 30616022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
    John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
    Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.
    de Veer RC; van Hooff MC; Corpechot C; Thorburn D; Invernizzi P; Lammers WJ; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Parés A; Mason AL; Kowdley KV; Trivedi PJ; Hirschfield GM; Goet JC; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Hansen BE; Harms MH; van der Meer AJ;
    Am J Gastroenterol; 2023 Jul; 118(7):1196-1203. PubMed ID: 36621963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis.
    Gordon SC; Wu KH; Lindor K; Bowlus CL; Rodriguez CV; Anderson H; Boscarino JA; Trudeau S; Rupp LB; Haller IV; Romanelli RJ; VanWormer JJ; Schmidt MA; Daida YG; Sahota A; Vincent J; Zhang T; Li J; Lu M;
    Am J Gastroenterol; 2020 Feb; 115(2):262-270. PubMed ID: 31985529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
    Harms MH; Lammers WJ; Thorburn D; Corpechot C; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Dalekos GN; Bruns T; Parés A; Mason AL; Verhelst X; Kowdley KV; Goet JC; Hirschfield GM; Hansen BE; van Buuren HR;
    Am J Gastroenterol; 2018 Feb; 113(2):254-264. PubMed ID: 29231188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
    J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
    Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.
    Shaheen AA; Kaplan GG; Almishri W; Vallerand I; Frolkis AD; Patten S; Swain MG
    PLoS One; 2018; 13(4):e0194839. PubMed ID: 29617396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.